Acticor Biotech SA
PAR:ALACT
Intrinsic Value
The intrinsic value of one ALACT stock under the Base Case scenario is 30.74 EUR. Compared to the current market price of 0.25 EUR, Acticor Biotech SA is Undervalued by 99%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Fundamental Analysis

Revenue & Expenses Breakdown
Acticor Biotech SA
Balance Sheet Decomposition
Acticor Biotech SA
Current Assets | 9.3m |
Cash & Short-Term Investments | 3.9m |
Receivables | 4.4m |
Other Current Assets | 986k |
Non-Current Assets | 461k |
Long-Term Investments | 439k |
PP&E | 22k |
Free Cash Flow Analysis
Acticor Biotech SA
EUR | |
Free Cash Flow | EUR |
Earnings Waterfall
Acticor Biotech SA
Revenue
|
0
EUR
|
Operating Expenses
|
-17.6m
EUR
|
Operating Income
|
-17.6m
EUR
|
Other Expenses
|
-1.1m
EUR
|
Net Income
|
-18.6m
EUR
|
ALACT Profitability Score
Profitability Due Diligence
Acticor Biotech SA's profitability score is 43/100. The higher the profitability score, the more profitable the company is.
Score
Acticor Biotech SA's profitability score is 43/100. The higher the profitability score, the more profitable the company is.
ALACT Solvency Score
Solvency Due Diligence
Acticor Biotech SA's solvency score is 45/100. The higher the solvency score, the more solvent the company is.
Score
Acticor Biotech SA's solvency score is 45/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ALACT Price Targets Summary
Acticor Biotech SA
Dividends
Current shareholder yield for ALACT is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?